Lantern Pharma Inc. announced that Leslie W. Kreis, Jr., the Managing Principal at Steelhead Capital Management, LLC, managing partner and co-founder of Bios Equity Partners, LP and Bios Equity Partners II, LP, and a member of Lantern Pharma's Board of Directors since 2019, has advised Lantern's Board of his determination not to stand for reelection as a Director at Lantern's Annual Meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.18 USD | -1.44% | -1.59% | +44.39% |
05-24 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
05-09 | Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.39% | 66.49M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+38.39% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Announces Leslie W. Kreis, Jr. Not to Stand for Reelection as A Director